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Abstract
Background: MicroRNAs (miRNAs) are short noncoding RNAs (approximately 22 nucleotides in length) that play
important roles in colorectal cancer (CRC) progression through silencing gene expression. Numerous
dysregulated miRNAs simultaneously participate in the process of colon cancer development. However, the
detailed mechanisms and biological functions of co-expressed miRNA in colorectal carcinogenesis have yet to be
fully elucidated.
Results: The objective of this study was to identify the dysfunctional miRNAs and their target mRNAs using a wet-
lab experimental and dry-lab bioinformatics approach. The differentially expressed miRNA candidates were
identified from 2 miRNA profiles, and were confirmed in CRC clinical samples using reported target genes of
dysfunctional miRNAs to perform functional pathway enrichment analysis. Potential target gene candidates were
predicted by an in silico search, and their expression levels between normal and colorectal tumor tissues were
further analyzed using real-time polymerase chain reaction (RT-PCR).
We identified 5 miRNAs (miR-18a, miR-31, miR-96, miR-182, and miR-224) and 10 miRNAs (miR-1, miR-9, miR-10b,
miR-133a, miR-143, miR-137, miR-147b, miR-196a/b, and miR-342) that were significantly upregulated and
downregulated in colon tumors, respectively. Bioinformatics analysis showed that the known targets of these
dysregulated miRNAs simultaneously participated in epithelial-to-mesenchymal transition (EMT), cell growth, cell
adhesion, and cell cycles. In addition, we identified that several pivotal target gene candidates may be
comodulated by dysfunctional miRNAs during colon cancer progression. Finally, 7 candidates were proven to be
differentially expressed, and had an anti-correlationship with dysregulated miRNA in 48 CRC samples.
Conclusion: Fifteen dysfunctional miRNAs were engaged in metastasis-associated pathways through comodulating
7 target genes, which were identified by using a multi-step approach. The roles of these candidate genes are
worth further exploration in the progression of colon cancer, and could potentially be targets in future therapy.
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Background
Colorectal cancer (CRC) is one of the most common
types of cancer in humans, and is the third leading
cause of cancer-related death worldwide [1]. It is the
consequence of a multi-step process caused by different
genetic and epigenetic changes in numerous genes.
MicroRNAs (miRNAs) are a class of non-protein coding
RNA molecules of 18-25 nucleotides that exert their
function on the base pairing between the seed region of
miRNAs and the 3’-untranslated regions (3’-UTR) of
target genes. Based on the degree of the complementary
pairing between miRNAs and mRNAs, miRNAs either
repress translation or promote the degradation of the
mRNAs of target genes [2]. In the past decade, consider-
able evidence has shown that miRNAs are involved in
the pathogenesis of human cancer, including CRC [2-7].
An miRNA profiling is an effective approach for high-
throughput identification of dysregulated miRNAs dur-
ing CRC progression, and numerous dysregulated miR-
NAs in colon cancer have been identified in previous
studies [8-12].
The expression of tumor-suppressive miRNA usually
suppresses tumor progression through silencing onco-
gene expression, and oncogenic miRNA frequently inhi-
bits tumor-suppression gene expression, resulting in
accelerating carcinogenesis. In colon cancer, most stu-
dies have focused on understanding the biological func-
tions of several individual miRNAs, using both in vitro
wet-lab experimental and in silico bioinformatics
approaches, which provided invaluable information on
miRNA-mRNA interactions. Even though miRNAs have
been shown to target at genes involved in crucial steps
within the protein interaction network [13]. It’s been
known that miRNAs usually repressed their target gene
expressions slightly and alteration of an individual
miRNA is insufficient to cause CRC. Therefore, in this
study we are especially interested in the consequence of
changes of a group of miRNAs in CRC. For those miR-
NAs that are changed systematically, the influence from
a group of miRNAs is generally complex because of the
regulation of an abundance of target genes. To further
understand the detailed influences of miRNAs, the con-
cept of miRNA regulatory modules (MRMs) was intro-
duced [14-17]. MRMs are groups of miRNAs and their
target genes that are thought to work together as a
module, and that have correlated functions or are
involved in similar biological processes. In 2005, Yoon
and De Micheli suggested a method to identify MRMs
that was based on miRNAs and their predicted target
genes [16]. Since then, other methods have been proposed
to identify modules from miRNA and mRNA expression
profiles [14,15,17]. These studies have found that MRMs
are highly enriched in known sets of biological pathways
or GO biological process and shown that these MRMs
may potentially serve as a model for understanding pheno-
type alterations or cancer pathogenesis.
In this study, we identified differentially expressed
miRNAs in clinical samples of colon cancer, and then
used the known targets for these miRNAs to accomplish
the identification of potentially affected pathways. Differ
from previous studies which used both miRNA and
mRNA profiles to obtain a regulatory modules, we take
advantage of pathway information to identified impor-
tant target genes. Based on these pathways, we selected
several potential candidate genes involved in colorectal
progression. Our results provide biological evidence to
support the hypothesis that miRNAs work as a team to
regulate the expression of multiple targets, which leads
to the alteration of cellular processes and specific biolo-
gical pathways.
Methods
Clinical samples and RNA extraction
48-paired tumor and adjacent normal mucosa samples,
and 8-paired metastatic liver tumor, primary tumor, and
adjacent mucosa samples were obtained from CRC
patients who underwent surgical operation at the
Department of Surgery, Veterans General Hospital in
Taipei, Taiwan. Informed consent was obtained from all
patients. Among the 8 metastatic liver cancer patients, 2
patients were selected that exhibited metastatic liver
tumors, primary tumors, and adjacent mucosa samples
for ABI TaqMan low-density miRNA array analysis
(Applied Biosystems, Foster City, CA, USA). The total
RNA of the fresh tumor and non-tumor specimens was
extracted using TRIzol reagent (Invitrogen, USA)
according to the manufacturer instructions. In brief, tis-
sue samples were homogenized in a 1 mL TRIzol
reagent and mixed with 0.2 mL chloroform to extract
protein, and the RNA was then precipitated using 0.5
mL isopropanol. The concentration, purity, and the
amount of total RNA were determined using a Nano-
Drop 1000 spectrophotometer (NanoDrop Technologies
Inc., USA).
Stem-loop reverse transcription and real-time
polymerase chain reaction
The primers were designed to detect mature miRNAs
for stem-loop RT-PCR according to the methods
described by Chen et al. [18]. One microgram of total
RNA was reverse-transcribed using a stem-loop RT
reaction with RT primers and SuperScript III Reverse
Transcriptase according to the user manual (Invitrogen,
Carlsbad, CA, USA). The reaction was performed under
the following incubation conditions: 30 min at 16 °C,
followed by 50 cycles of 20 °C for 30 s, 42 °C for 30 s,
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and 50 °C for 1 s. The enzyme was subsequently inacti-
vated by incubation at 85 °C for 5 min. RT-PCR reac-
tions were performed using an miRNA-specific forward
primer and a universal reverse primer, and were con-
ducted at 94 °C for 10 min, followed by 40 cycles of 94
°C for 15 s, and 60 °C for 32 s. Gene expression was
detected using a SYBR Green I assay (Applied Biosys-
tems, Foster City, CA, USA), and the expression levels
of the miRNAs were normalized to that of U6. The
expression levels of the predicted target genes were
examined using RT-PCR analysis with a gene-specific
primer, and were normalized to S26. The expression
levels of the target genes were evaluated between the
normal and cancer tissues using a paired t test. The dif-
ference was considered to be significant if the P value
was less than 0.05. The individual primers used in this
study are shown in Additional File 1.
Pathway enrichment analysis
Known targets of the 15 dysregulated miRNAs were
used to establish which biological processes or pathways
these miRNAs might influence. A list of the known tar-
gets of each selected miRNA was identified using the
MetaCore database. Both targets for upregulated miR-
NAs and targets for downregulated miRNAs were used
for enrichment analysis using MetaCore. These stati-
stically enriched pathways were further investiga-
ted to select candidate genes for further validation
experiments.
Selection of target genes for further investigation
After identifying the pathways potentially affected by the
differentially expressed miRNAs, further validation was
required to determine whether these reported targets
were influenced in actual biological samples. Several
enriched pathways relating to cancer development were
targeted for study, such as cell proliferation, cell cycles,
cytoskeleton remodeling, cell adhesion, EMT, and apop-
tosis. Within those pathways, the previously reported
targets were selected for further examination. In addi-
tion to the reported miRNA targets, this study
attempted to identify other potential targets. Potential
miRNA targets were downloaded from TargetScan
(Release 6.0: November 2011) [19]. Within the predicted
targets, those with a context score greater than -0.2
were removed first because they were predicted to be
low-efficacy targets [20,21]. After a list of high-efficacy
targets was obtained, targets that were regulated by
more than one differentially expressed miRNA were
selected, except for genes targeted by both miR-196a
and miR196b. Because miR-196a and miR-196b are in
the same family and have the same group of predicted
target genes, their target genes were treated as if they
were targeted only once. Among those predicted high
efficacy and co-regulated targets, 7 of them which were
located at pathways that we previously selected, were
noteworthy. These targets were further investigated to
determine whether their expression patterns were con-
sistent with the expected trends.
Results
Identifying miRNAs differentially expressed in colorectal
carcinoma
Metastasis is the major cause of death in colon cancer
patients. In this study, we attempted to identify dysfunc-
tional miRNAs that are involved in CRC metastasis and
progression. Therefore, we performed the expression
profile of human miRNAs in primary cancer, its liver
metastasis, and the corresponding normal mucosa of 2
CRC patients by using an ABI TaqMan low-density
miRNA array approach. After completing the miRNA
profiling of the 2 CRC samples, we identified the top 20
upregulated and top 20 downregulated miRNAs in
tumor or liver metastases (Table 1). To further confirm
these miRNAs, we examined the expression by using
stem-loop RT-PCR in 6 additional CRC samples that
contained primary tumors, and their corresponding liver
metastases and mucosa. Finally, we identified 5 miRNAs
(miR-18a, miR-31, miR-96, miR-182, and miR-224) and
10 miRNAs (miR-1, miR-9, miR-10b, miR-133a, miR-
143, miR-137, miR-147b, miR-196a and 196b, and miR-
342) that are frequently upregulated and downregulated
in both colon tumors and liver metastasic tissue, respec-
tively, compared with the adjacent normal and tumor
areas (Additional File 2).
Dysregulated miRNA coexpression in colon cancer
We further examined the expression level of miRNA
candidates in 48 CRC samples by using the stem-loop
RT-PCR approach. The expression levels of miR-18a,
miR-31, miR-96, miR-182, and miR-224 were signifi-
cantly upregulated in at least 70% of the CRC samples
(P < 0.0001). In other groups, we found that miR-1,
miR-9, miR-10b, miR-133a, miR-137, miR-143, miR-
147b, miR-196a/b, and miR-342 were significantly
downregulated in at least 70% of the samples (P <
0.0001) (Figure 1). These results indicated that these
miRNA candidates may play a pivotal role in colon can-
cer progression. By reviewing previous studies, we
learned that most of these miRNAs have been reported
as differentially expressed miRNA in colon cancer
[5,22-24]. However, a comprehensive understanding of
the biological functions of these miRNAs in CRC is
lacking, particularly for miR-10b, miR-96, miR-133a,
miR-147b, miR-196a/b, and miR-342. We further
observed that the 5 upregulated miRNAs simultaneously
exhibited upregulation in 62% of the CRC samples (30
out of 48) and the 10 downregulated miRNAs were
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simultaneously silenced in 58% of the CRC samples (28
out of 48). Our data implies that these miRNAs tend to
dysregulate simultaneously in CRC, and these miRNAs
may regulate cancer-associated signaling pathways by
comodulating a group of critical genes in CRC.
Biological pathways analysis
Pathway enrichment analysis enables us to comprehen-
sively investigate the association between a group of
miRNAs and cancer progression by using computational
methods [6,25,26]. However, the high false-positive rates
of these prediction programs result in low reliability. To
more precisely determine what specific biological path-
ways are regulated by these differentially expressed miR-
NAs, we used known target genes to perform pathway
enrichment analysis in this study. First, we downloaded
366 and 741 reported known targets for these upregu-
lated and downregulated miRNAs respectively from the
MetaCore database that have high-quality, manually-
curated miRNA and miRNA target information. We
further performed pathway enrichment statistical tests
on these known target gene sets. MetaCore calculates
probability according to a hypergeometric distribution
formula, and provides the final P-value estimations of
the likelihood of a particular pathway being enriched
and selected at random. For a list of interested genes, if
the number of interested genes found in one pathway is
significantly higher than expected, then that particular
pathway is, by definition, enriched and is reported as
such. Pathway enrichment analysis provides us with
clues regarding which biological functions or specific
pathways these known targets may contribute to on a
cellular level. The top 10 enriched pathways in Figure
2A show that most of these enriched pathways are
related to cancer development or metastasis, such as cell
proliferation, cell cycles, cytoskeleton remodeling, cell
adhesion, or EMT. Regarding the enriched processes
(Figure 2B), many are also related to EMT regulation,
cell growth, angiogenesis, cell adhesion, cell cycles, and
so on. Our results indicated that the targets of the dif-
ferentially expressed miRNAs are predominantly
involved in the development and metastasis of CRC.
Locating potential target genes of dysregulated miRNAs
in colon cancer
Because miRNAs could act as either oncomiR or tumor-
suppressor miRs depending on their target genes, we
selected several known and predicted target genes to
further examine whether their expression levels were
changed in colon cancer samples after statistical path-
ways enrichment analysis. Numerous target prediction
Table 1 The top 20 most differential up- and
downregulated miRNAs are shown from 2 miRNA
profiles.
Upregulated miRNAs T1a M1b T2c M2d
miR-183 25.6 22.9 3.8 9.1
miR-31 22.5 18.6 5.7 1 3.8
miR-135b 8.6 6.6 18.2 46.5
miR-96 8.3 8.6 6.7 65.3
miR-224 7.1 4.7 13.1 43.1
miR-182 5.2 5.7 2.1 6.5
miR-193a-5p 4.7 3.7 1.4 3.5
miR-409-5p 4.7 11.8 1 8.2
miR-18b 4.3 1.5 10.9 8.7
miR431 3.8 7.4 10.1 11
miR-18a 3.7 1.3 5.1 6.8
miR-221 3.2 1.1 4.8 5.3
miR-424 2.3 2 1.6 7.2
miR-25 1.6 1.9 3.8 5.1
miR-29b 1.5 2.6 2.4 7.3
miR-455-3p 1.5 2.2 9.7 46.2
miR-93 1.4 2.2 5.3 6.9
miR-483-5p 1.1 9.7 19.5 128
miR-455-5p 1.1 2.1 2.7 5.5
miR-122 1 201441.3 1 1370
Downregulated miRNAs
miR-137 0.005 0.004 0.108 0.136
miR-133b 0.025 0.03 0.403 0.271
miR-133a 0.026 0.021 0.236 0.052
miR-138 0.038 0.061 0.566 0.255
miR-204 0.043 0.697 0.066 0.479
miR-342-3p 0.073 0.619 0.059 0.064
miR-9 0.079 0.223 0.291 0.447
miR-195 0.085 0.19 0.517 0.287
miR-143 0.097 0.118 0.435 0.366
miR-139-5p 0.112 2.1 0.167 0.87
miR-140-3p 0.113 0.269 0.343 0.554
miR-196a/b 0.125 0.001 0.031 0.015
miR-1 0.146 0.012 0.586 0.384
miR-10b 0.156 0.037 0.779 0.279
miR-218 0.166 0.297 0.213 1.2
let-7b 0.203 0.506 0.726 0.646
miR-149 0.204 0.162 0.174 0.801
miR-145 0.205 0.153 0.438 0.514
miR-147b 0.251 0.152 0.122 0.025
miR-215 0.489 0.23 0.318 0.619
The expression patterns of 15 miRNA candidates that proved consistent with
the profile data after further confirmation in addition to the 6 CRC samples
are shown in bold.
a. Primary colon cancer: adjacent mucosa from patient 1
b. Liver metastases: adjacent mucosa from patient 1
c. Primary colon cancer: adjacent mucosa from patient 2
d. Liver metastases: adjacent mucosa from patient 2
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tools for miRNAs have been developed, such as PITA,
miRanda, PicTar, and miRBase Targets [27-30]. From
them, we used the TargetScan tool, which provides tar-
get predictions through the conserved complementarily
to the seed region of miRNAs. Although TargetScan is
shown to have the best performance [31], a high false-
positive rate is still a problem because each miRNA has
up to several hundred targets. Therefore, reasonably
narrowing down the target genes enables us to more
efficiently locate the potential target genes that partici-
pate in colon cancer progression. In this study, we
applied 2 concepts to locate the potential target genes:
(1) Co-expressed miRNAs are believed to share similar
biological functions and participate in the same signal-
ing pathways in CRC; and (2) co-expressed miRNAs
may comodulate the same critical gene, which results in
efficiently blocking or promoting the signaling pathway
progression. Therefore, we selected candidate target
genes that conformed to these 2 concepts. We consid-
ered both predicted and reported data, and obtained a
list of candidates, as shown in Table 2.
For known targets, we selected the 6 most reported
targets in the enriched pathways, excluding those that
have no predicted target site in TargetScan or were pre-
dicted to target only controversial dysregulated miRNAs;
that is, we selected 3 groups of known targets. The first
2 target groups have been reported and predicted as
only downregulated miRNAs (Group III) or as only
upregulated miRNAs (Group IV). The third group of
targets reportedly targets either up- or downregulated
miRNA and is predicted by both upregulated and down-
regulated miRNAs (Group V). For these predicted tar-
gets, we only considered the targets which were
predicted to be targeted by more than one of our
Figure 1 Expression levels of 15 dysregulated miRNAs in 48 CRC patients. Expression of 15 miRNAs in the CRC tissues from 48 patients
was analyzed using quantitative stem-loop PCR with U6 as an internal control. The percentage of upregulation or downregulation of individual
miRNA in the 48 CRC patients is shown at the top of each panel. All samples were assessed in triplicate and analyzed using paired t tests (P <
0.05 was considered significant; NS: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001).
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selected differentially expressed miRNAs to increase our
accuracy. From the predicted targets downloaded from
TargetScan, there are 179 predicted targets co-regulated
by at least 2 upregulated miRNAs and 172 predicted
targes co-regulated by at least 2 downregulated miRNAs.
Among those predicted co-regulated targets, we further
selected 7 that are involved in the enriched pathways we
previously derived from known targets. Within these 7
predicted targets, 3 are potential targets for downregu-
lated miRNAs (Group I), and 4 are potential targets for
upregulated miRNAs (Group II). Based on the concepts
of co-function and co-modulation, we reasonably
reduced our candidate list, which was composed of both
reported and predicted potential target genes (Table 2).
Examination of the expression levels of miRNA targets
Table 2 presents 27 pivotal genes (20 known and 7 pre-
dicted target genes), which may be co-regulated by
dysregulated miRNA, that may contribute to the
impairment of several biological functions (EMT regula-
tion, cell growth, cell adhesion, and cell cycles) during
colorectal progression. We further examined the expres-
sion levels of these target genes in 48 CRC samples by
using the RT-PCR approach. As shown in Figure 3 and
Table 2, 14 out of the 27 candidate genes showed signif-
icant differential expression (including 8 upregulation
and 6 downregulation), and 13 out of the 27 gene tran-
script levels demonstrated no significant difference in
the CRC tissues compared to the adjacent normal tis-
sues. In general, when miRNA regulated its target genes
by directly destroying the mRNA, the miRNA expres-
sion level should be negatively correlated with the tar-
geted gene expression in the cells. Therefore, the target
genes should have an increased expression level in the
tumor samples, and the target genes should have been
identified from the downregulated miRNAs sets (Groups
I and III). Conversely, target genes targeted by upregu-
lated miRNAs sets should have decreased expression
Figure 2 Pathway and process enrichment results of reported target genes of 15 dysregulated miRNAs. (A) The respective pathway
enrichment results and (B) the process enrichment results of known targets for both upregulated miRNA (orange) and downregulated miRNA
(blue) were generated by MetaCore. The horizontal axis is the negative log transformation of the P value, which indicates the probability that
these processes (or pathways) are raised by chance. In pathway enrichment, numerous pathways related to cancer, such as cell proliferation, cell
cycles, cytoskeleton remodeling, and EMT, are statistically enriched. A similar outcome is found in process enrichment, and many cancer- or
metastasis-correlated processes are enriched.
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levels (Groups II and IV). According to our data, 7 out
of the 27 candidate genes’ expression levels were
observed to be negatively correlated with their individual
miRNAs regulators. Among them, MYH9 was shown to
provide an oncogenesis role in cancer cell migration
[32,33]. Our data indicates that MYH9 may be a puta-
tive novel target gene of miR-133a and miR-9, and the
upregulated expression level of MYH9 may be caused
by the low expression of miR-133a and miR-9 in CRC
(Figure 3, Group I).
We also identified 3 cancer-associated genes, GAN13,
HBEGF, and PPP2R3A, with significantly decreasing
expression levels in colon cancer (Figure 3, Group II).
They were selected from predicted target genes of miR-
182 and miR-96 in Group II. Among them, PPP2R3A
was implicated as a tumor-suppressor gene contributing
to cell transformation [34]. However, we do not have a
complete understanding of the regulation mechanism of
PPP2R3A and its relationship with miRNAs in CRC. In
this study, we provided a finding that miR-182 and miR-
96 may contribute to silence PPP2R3A expression in
CRC. In Group III, we identified 3 putative candidates,
Collagen I, Cyclin D1, and Versican, which were signifi-
cantly upregulated in CRC tissues. Although previous
studies have shown that miR-196a directly targeted Col-
lagen I, and miR-143 repressed the expression of Cyclin
D1 and Versican [35-39], the regulation mechanism of
Collagen I, Cyclin D1, and Versican by miRNAs in CRC
is not understood. In addition, we have also identified
novel miRNAs candidates, miR-143, miR-1, and miR-9,
which have the potential to regulate Collagen I, Cyclin
D1, and Versican, respectively (Table 2). In our data, we
have observed conflicting results in the expression pat-
tern between the miRNAs and anticipated target genes.
These conflicting results may be because one gene is
usually regulated by a complex mechanism. In addition,
previous systematic genome-wide studies have indicated
that the regulation effects of miRNAs may be detectable
at the protein-synthesis level, although no significant
changes may exist at the mRNA expression level [31,40].
Discussion
MiRNAs play either a tumor-suppressive or an onco-
genic role depending on their target genes, and may
Table 2 Target genes of 15 dysregulated miRNA were selected for RT-PCR examination in this study
Target type Group Gene Symbol miRNA Expression level in colon cancer#
predicted Group I GDNF miR133a, miR9 Down**
miRNA ↓ MYH9 miR133a, miR9 Up*
RNF111 miR1, miR9 Down*
GroupII GNA13 miR182, miR96 Down*
miRNA ↑ HBEGF miR182, miR96 Down***
LAMC1 miR182, miR96 Up***
PPP2R3A miR182, miR96 Down***
known Group III Bim miR10b NS
miRNA ↓ CDC42 miR1 NS





calmodulin miR196a, miR143 NS
Group IV ATM miR18a NS
miRNA ↑ FBXW7 miR182 NS
FZD3 miR31, miR182 NS
SMAD2 miR18a Up**
Group V CREB1 miR10b, miR182 Up***
FBXW11 miR133, miR96, miR182 NS
Mixed IGF1 miR1, miR18a Down***
MAP3K14 miR137, miR31 NS
MSN miR133a, miR96 Up***
PDGFRA miR342, miR182 NS
SMAD4 miR1, miR224 NS
RASA1 miR1, miR96, miR182, miR31 NS
# Paired t test results: NS: not significant, * P < 0.05, ** P <0.01, *** P < 0.001
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modulate cancer growth, cell cycles, and migration in
CRC [5,22,23,41]. In general, multiple miRNAs are
simultaneously dysfunctional during carcinogenesis. One
miRNA regulates the expression of more than one tar-
get, and one gene can be regulated by more than one
miRNA. This type of many-to-many relationship com-
plicates the study of relevance between miRNAs and
their targets, and results in difficulties in comprehen-
sively investigating the altered expression of a group of
miRNAs. It has been proposed that miRNAs work
together to regulate their target genes in the regulatory
network, which differs from previous MRM identifica-
tion methods [14-17] that considered the sequence simi-
larity or expression profiles, but not biological pathways.
These MRMs are likely to simultaneously involve several
biological pathways. MRMs identified in a previous
study were shown to be enriched in biological pathways,
and that these MRMs are likely to be functionally corre-
lated [17]. In addition, regarding pathways, the predicted
targets for differentially expressed miRNAs in cancer
cells show a broad range of changes, which provide
clues to explain abnormal phenotypical alterations [42].
Together with these studies, our results suggest that,
beginning with pathway analysis, one may successfully
integrate several crucial targets of dysregulated miRNAs
to provide an explanation of cancer development.
Compared with previous studies, most of dysfunc-
tional miRNAs detected in this study had been reported
in colorectal cancer [5,22-24]. However, the biological
functions of these miRNAs in CRC remained unclear,
particularly for miR-10b, miR-96, miR-133a, miR-147b,
miR-196a/b, and miR-342. In this study, a comodulated
concept was adopted to reasonably identify the miRNA
targets. To locate the modules of these differentially
expressed miRNAs that may participate in colon cancer;
we constructed miRNA and mRNA relationships by
using direct targets. We focused on direct targets
because a previous study suggested that the high
through-put of mRNA and miRNA expression profiles
did not yield more accurate prediction outcomes of the
protein product levels [43] compared to the direct tar-
gets. In order to obtain more reliable miRNA-mRNA
relationships, we used reported targets instead of pre-
dicted targets that were used in previous studies
[14,15,17,44]. Accordingly, these targets should improve
the accuracy of potentially altered pathways. Numerous
metastasis- and cancer-related pathways were enriched.
Our results also support the theory of MRMs that these
miRNAs target at many targets and work as a module,
which leads to abnormalities in cancer development or
metastases.
Our approach toward potential miRNA target gene
selection, namely the use of co-regulation, the same
pathway, and the context score, may also provide biolo-
gically reasonable rules for novel miRNA target predic-
tion fields. Although not all of our predicted targets
were supported through qPCR, the potential targets
selected through these criteria are still convincing. For
example, when we prepared this manuscript, Rasheed et
al. reported that miR-182 can silence GAN13 protein
expression, but cannot alter mRNA levels by targeting
its 3’-UTR, which results in inhibiting prostate cancer
cell migration and invasion [45]. Their results support
our findings in which GNA13 is predicted as a putative
novel target of miR-182, and its transcriptional levels
have a slight negative correlation with miR-182 expres-
sion in clinical samples (Table 2). Although the detailed
functions of miR-182 silencing the GNA13 expression
Figure 3 Expression levels of target gene candidates of dysregulated miRNAs in 48 CRC patients. Expression of target genes in the CRC
tissues of 48 patients was analyzed using quantitative stem-loop PCR with S26 as an internal control. All samples were assessed in triplicate and
analyzed using paired t tests (P < 0.05 was considered significant; NS: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001).
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in colon cancer requires further investigation, their data
helps support the reliability of our strategy of novel tar-
get selection.
Through further experimental validation, we learned
that certain target mRNA expression levels changed in
an unexpected manner. This inconsistency has also been
observed in a recent study, in which the expression
levels of miRNAs and genes in the same MRM were
associated by up to 69% [17]. Although we only retained
reported targets and high-efficacy and coregulated pre-
dicted targets, several of these exhibited nonsignificant
or conflicting expression patterns. One gene is usually
regulated by numerous regulatory factors in actual bio-
logical systems, and the regulatory effects of miRNAs
may be observed at either the mRNA expression level or
the protein synthesis level [31,40]. For example, based
merely on miRNA regulation, we expected the expres-
sion level of GDNF should be upregulated, but some
other factors have already been shown to involve in reg-
ulation of GDNF expression in cancers. DNA hyper-
methylation contributes to the low expression of GDNF
in several human cancers [46-48]. Satio et al. also found
that the promoter region of GDNF was more highly
methylated in active inflamed mucosa than in quiescent
mucosa in ulcerative colitis patients [49]. These results
could address why GDNF significantly reduced its
expression in CRC compared to the adjacent normal tis-
sue. Here, we only focused on investigating the mRNA
expression levels of targeted genes because of the scar-
city of clinical samples, and budgetary limitations.
Although the mRNA expression levels of the targeted
genes did not completely fit our expectations because
they were under the regulation of the miRNAs, these
expression levels coupled with the expression-level
changes of the miRNA from the clinical samples are
invaluable.
Conclusion
Fifteen dysregulated miRNAs were identified by screening
clinical samples. We have successfully examined the
major biological functions and signaling pathways of
these co-expressed miRNAs, and have provided an
approach to reasonably narrow down the target genes of
co-expressed miRNAs in colon cancer. Both dysfunc-
tional miRNAs and their comodulating target genes are
worth further exploration in the progression of colon
cancer, and could potentially be targets in future therapy.
Additional material
Additional File 1: Sequences of primers for miRNA and target gene
detection
Additional File 2: Expression levels of dysregulated miRNAs in 6
liver metastasis patients. Expression of miRNAs was examined in
primary tumors, metastatic liver tumors, and the corresponding normal
mucosa of 6 CRC patients using RT-PCR with U6 as an internal control.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TWC executed this study and prepared the draft of the manuscript. YTT and
SYY were responsible for RT-PCR validation. SCL and MRH performed
pathway enrichment analysis. THY, LYH, PFL, CWS and HWP assisted with the
tissue preparation and RNA extraction. WSC, WCL, TTW and KWT supervised
the study and edited the manuscript.
Acknowledgements
This work was supported by grants from Kaohsiung Veterans General
Hospital, Taiwan (VGHKS 102-005 and VGHKS102-074).
Declarations
Publication of this article was funded by National Science Council, Taiwan
(NSC 102-2320-B-010-029).
This article has been published as part of BMC Genomics Volume 14
Supplement 5, 2013: Twelfth International Conference on Bioinformatics
(InCoB2013): Computational biology. The full contents of the supplement are
available online at http://www.biomedcentral.com/bmcgenomics/
supplements/14/S5.
Authors’ details
1Department of Surgery, Veterans General Hospital, Taipei, Taiwan.
2Molecular Medicine Research Center, Chang Gung University, Taoyuan,
Taiwan. 3Bioinformatics Center, Chang Gung University, Taoyuan, Taiwan.
4Department of Biotechnology and Laboratory Science in Medicine and
Institute of Biotechnology in Medicine, National Yang Ming University, Taipei,
Taiwan. 5Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
6Department of Medical Education and Research, Kaohsiung Veterans
General Hospital, Kaohsiung, Taiwan. 7Department of Radiation Oncology,
Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. 8Clinical Genomics
& Proteomics Core Laboratory, Department of medical research, Kaohsiung
Chang Gung Memorial Hospital and Chang Gung University College of
Medicine, Kaohsiung, Taiwan. 9Genomics Research Center, Academia Sinica,
Taipei, Taiwan. 10Department of Surgery, Kaohsiung Veterans General
Hospital, Kaohsiung, Taiwan. 11School of Medicine, Yang-Ming University,
Taipei, Taiwan.
Published: 16 October 2013
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA: a cancer journal for clinicians 2011, 61(2):69-90.
2. Pan HW, Li SC, Tsai KW: MicroRNA Dysregulation in Gastric Cancer.
Current pharmaceutical design 2013, 19(7):1273-1284.
3. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R,
Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of
human solid tumors defines cancer gene targets. Proceedings of the
National Academy of Sciences of the United States of America 2006,
103(7):2257-2261.
4. Li X, Zhang G, Luo F, Ruan J, Huang D, Feng D, Xiao D, Zeng Z, Chen X,
Wu W: Identification of aberrantly expressed miRNAs in rectal cancer.
Oncology reports 2012, 28(1):77-84.
5. Schetter AJ, Harris CC: Alterations of microRNAs contribute to colon
carcinogenesis. Seminars in oncology 2011, 38(6):734-742.
6. Chang HT, Li SC, Ho MR, Pan HW, Ger LP, Hu LY, Yu SY, Li WH, Tsai KW:
Comprehensive analysis of microRNAs in breast cancer. BMC genomics
2012, 13(Suppl 7):S18.
7. Chen WS, Leung CM, Pan HW, Hu LY, Li SC, Ho MR, Tsai KW: Silencing of
miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in
colorectal cancer. Oncology reports 2012, 28(3):1069-1076.
8. Callari M, Dugo M, Musella V, Marchesi E, Chiorino G, Grand MM,
Pierotti MA, Daidone MG, Canevari S, De Cecco L: Comparison of
Chen et al. BMC Genomics 2013, 14(Suppl 5):S12
http://www.biomedcentral.com/1471-2164/14/S5/S12
Page 9 of 10
microarray platforms for measuring differential microRNA expression in
paired normal/cancer colon tissues. PloS one 2012, 7(9):e45105.
9. Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T,
Kure EH: Differential expression of miRNAs in colorectal cancer:
comparison of paired tumor tissue and adjacent normal mucosa using
high-throughput sequencing. PloS one 2012, 7(4):e34150.
10. Monzo M, Navarro A, Bandres E, Artells R, Moreno I, Gel B, Ibeas R,
Moreno J, Martinez F, Diaz T, et al: Overlapping expression of microRNAs
in human embryonic colon and colorectal cancer. Cell research 2008,
18(8):823-833.
11. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H,
Sugihara K, Mori M: Over- and under-expressed microRNAs in human
colorectal cancer. International journal of oncology 2009, 34(4):1069-1075.
12. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ: Initial study of
microRNA expression profiles of colonic cancer without lymph node
metastasis. Journal of digestive diseases 2010, 11(1):50-54.
13. Liang H, Li WH: MicroRNA regulation of human protein protein
interaction network. RNA (New York, NY 2007, 13(9):1402-1408.
14. Joung JG, Hwang KB, Nam JW, Kim SJ, Zhang BT: Discovery of microRNA-
mRNA modules via population-based probabilistic learning.
Bioinformatics (Oxford, England) 2007, 23(9):1141-1147.
15. Tran DH, Satou K, Ho TB: Finding microRNA regulatory modules in
human genome using rule induction. BMC bioinformatics 2008, 9(Suppl
12):S5.
16. Yoon S, De Micheli G: Prediction of regulatory modules comprising
microRNAs and target genes. Bioinformatics (Oxford, England) 2005,
21(Suppl 2):ii93-100.
17. Zhang S, Li Q, Liu J, Zhou XJ: A novel computational framework for
simultaneous integration of multiple types of genomic data to identify
microRNA-gene regulatory modules. Bioinformatics (Oxford, England) 2011,
27(13):i401-409.
18. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M,
Xu NL, Mahuvakar VR, Andersen MR, et al: Real-time quantification of
microRNAs by stem-loop RT-PCR. Nucleic acids research 2005, 33(20):e179.
19. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA
targets. Cell 2005, 120(1):15-20.
20. Chen SJ, Chen HC: Analysis of targets and functions coregulated by
microRNAs. Methods in molecular biology (Clifton, NJ 2011, 676:225-241.
21. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP:
MicroRNA targeting specificity in mammals: determinants beyond seed
pairing. Molecular cell 2007, 27(1):91-105.
22. Akao Y, Nakagawa Y, Naoe T: MicroRNA-143 and -145 in colon cancer.
DNA and cell biology 2007, 26(5):311-320.
23. Faber C, Kirchner T, Hlubek F: The impact of microRNAs on colorectal
cancer. Virchows Arch 2009, 454(4):359-367.
24. Wu WK, Law PT, Lee CW, Cho CH, Fan D, Wu K, Yu J, Sung JJ: MicroRNA in
colorectal cancer: from benchtop to bedside. Carcinogenesis 2011,
32(3):247-253.
25. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y,
Yang Y, et al: Identification of miRNomes in human liver and
hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target
for hepatocellular carcinoma. Cancer cell 2011, 19(2):232-243.
26. Juhila J, Sipila T, Icay K, Nicorici D, Ellonen P, Kallio A, Korpelainen E,
Greco D, Hovatta I: MicroRNA expression profiling reveals miRNA families
regulating specific biological pathways in mouse frontal cortex and
hippocampus. PloS one 2011, 6(6):e21495.
27. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ: miRBase: tools for
microRNA genomics. Nucleic acids research 2008, 36(Database):D154-158.
28. Betel D, Wilson M, Gabow A, Marks DS, Sander C: The microRNA.org
resource: targets and expression. Nucleic acids research 2008,
36(Database):D149-153.
29. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P,
da Piedade I, Gunsalus KC, Stoffel M, et al: Combinatorial microRNA target
predictions. Nature genetics 2005, 37(5):495-500.
30. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E: The role of site
accessibility in microRNA target recognition. Nature genetics 2007,
39(10):1278-1284.
31. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP: The impact of
microRNAs on protein output. Nature 2008, 455(7209):64-71.
32. Xia ZK, Yuan YC, Yin N, Yin BL, Tan ZP, Hu YR: Nonmuscle myosin IIA is
associated with poor prognosis of esophageal squamous cancer. Dis
Esophagus 2012, 25(5):427-436.
33. Derycke L, Stove C, Vercoutter-Edouart AS, De Wever O, Dolle L, Colpaert N,
Depypere H, Michalski JC, Bracke M: The role of non-muscle myosin IIA in
aggregation and invasion of human MCF-7 breast cancer cells. The
International journal of developmental biology 2011, 55(7-9):835-840.
34. Sablina AA, Hector M, Colpaert N, Hahn WC: Identification of PP2A
complexes and pathways involved in cell transformation. Cancer research
2010, 70(24):10474-10484.
35. Kashiyama K, Mitsutake N, Matsuse M, Ogi T, Saenko VA, Ujifuku K, Utani A,
Hirano A, Yamashita S: miR-196a downregulation increases the
expression of type I and III collagens in keloid fibroblasts. The Journal of
investigative dermatology 2012, 132(6):1597-1604.
36. Honda N, Jinnin M, Kajihara I, Makino T, Makino K, Masuguchi S,
Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, et al: TGF-beta-
mediated downregulation of microRNA-196a contributes to the
constitutive upregulated type I collagen expression in scleroderma
dermal fibroblasts. J Immunol 2012, 188(7):3323-3331.
37. Khach Lai V, Ashraf M, Jiang S, Haider K: MicroRNA-143 is critical regulator
of cell cycle activity in stem cells with co-overexpression of Akt and
angiopoietin-1 via transcriptional regulation of Erk5/cyclin D1 signaling.
Cell cycle (Georgetown, Tex 2012, 11(4).
38. Wang X, Hu G, Zhou J: Repression of versican expression by microRNA-
143. The Journal of biological chemistry 2010, 285(30):23241-23250.
39. Lai VK, Ashraf M, Jiang S, Haider K: MicroRNA-143 is a critical regulator of
cell cycle activity in stem cells with co-overexpression of Akt and
angiopoietin-1 via transcriptional regulation of Erk5/cyclin D1 signaling.
Cell cycle (Georgetown, Tex 2012, 11(4):767-777.
40. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N:
Widespread changes in protein synthesis induced by microRNAs. Nature
2008, 455(7209):58-63.
41. Dong Y, Wu WK, Wu CW, Sung JJ, Yu J, Ng SS: MicroRNA dysregulation in
colorectal cancer: a clinical perspective. Br J Cancer 2011, 104(6):893-898.
42. Gusev Y: Computational methods for analysis of cellular functions and
pathways collectively targeted by differentially expressed microRNA.
Methods (San Diego, Calif 2008, 44(1):61-72.
43. Dong J, Jiang G, Asmann YW, Tomaszek S, Jen J, Kislinger T, Wigle DA:
MicroRNA networks in mouse lung organogenesis. PloS one 2010, 5(5):
e10854.
44. Kim S, Choi M, Cho KH: Identifying the target mRNAs of microRNAs in
colorectal cancer. Computational biology and chemistry 2009, 33(1):94-99.
45. Rasheed SA, Teo CR, Beillard EJ, Voorhoeve M, Casey PJ: MicroRNA-182 and
microRNA-200a control G-protein subunit alpha-13 (GNA13) expression
and cell invasion synergistically in prostate cancer cells. The Journal of
biological chemistry 2013.
46. Anglim PP, Galler JS, Koss MN, Hagen JA, Turla S, Campan M,
Weisenberger DJ, Laird PW, Siegmund KD, Laird-Offringa IA: Identification
of a panel of sensitive and specific DNA methylation markers for
squamous cell lung cancer. Molecular cancer 2008, 7:62.
47. Watanabe Y, Kim HS, Castoro RJ, Chung W, Estecio MR, Kondo K, Guo Y,
Ahmed SS, Toyota M, Itoh F, et al: Sensitive and specific detection of
early gastric cancer with DNA methylation analysis of gastric washes.
Gastroenterology 2009, 136(7):2149-2158.
48. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, Pfeifer GP: CpG
island hypermethylation in human astrocytomas. Cancer research 2010,
70(7):2718-2727.
49. Saito S, Kato J, Hiraoka S, Horii J, Suzuki H, Higashi R, Kaji E, Kondo Y,
Yamamoto K: DNA methylation of colon mucosa in ulcerative colitis
patients: correlation with inflammatory status. Inflammatory bowel
diseases 2011, 17(9):1955-1965.
doi:10.1186/1471-2164-14-S5-S12
Cite this article as: Chen et al.: Co-modulated behavior and effects of
differentially expressed miRNA in colorectal cancer. BMC Genomics 2013
14(Suppl 5):S12.
Chen et al. BMC Genomics 2013, 14(Suppl 5):S12
http://www.biomedcentral.com/1471-2164/14/S5/S12
Page 10 of 10
